Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow
Orazi, A.; Cooper, R.J.; Tong, J.; Gordon, M.S.; Battiato, L.; Sledge, G.W.; Kaye, J.A.; Kahsai, M.; Hoffman, R.
Experimental Hematology 24(11): 1289-1297
ISSN/ISBN: 0301-472X PMID: 8862439 Accession: 008579234
We examined the effects of recombinant human interleukin 11 (rhIL-11) on in vivo human hematopoiesis. Twelve women with advanced breast cancer and no evidence of bone marrow (BM) involvement were treated with 10, 25, 50, or 75 mu-g/kg/day of rhIL-11 administered subcutaneously for 14 consecutive days. Examination of bone marrow trephine biopsies obtained before and after rhIL-11 treatment revealed unchanged BM cellularity at all doses, and a statistically significant increase in megakaryocyte (MK) frequencies (from 0.5 +- 0.1% to 1.0 +- 0.3%) following administration of the two highest doses (p lt 0.001).